Collaborations

The company has collaboration agreements with the Foundation for Biomedical Research at the Puerta de Hierro University Hospital (Madrid, Spain) focused on conducting immunogenicity, pharmacokinetics and biodistribution studies in mice; the Centre for Applied Medical Research (CIMA, Pamplona, Spain) to address the in vivo efficacy of Trimerbody-based molecules in experimental models of cancer; and the Research Biomedicine Institute Alberto Sols (IIBm, Madrid, Spain) to assess the intracellular signaling events induced by specific candidate molecules. In addition, the company is collaborating with the Spanish National Cancer Research Center (CNIO, Madrid, Spain) to address the structures of the Trimerbody-based molecules.

Latest News

"Tumor-targeted costimulatory trimerbodies for cancer Immunotherapy”- A brief discussion with Juan Perez Villar, CEO, LEADARTIS.
07-06-2021

...

Diario ABC España y Cadena Cope: Investigadores crean un nuevo anticuerpo antitumoral más eficaz
01-06-2021

El director de la unidad de inmunoterapia del cáncer del Instituto de Investigación del Hospital...

Leadartis to present on May 26th, 2021 its business to the 17th Annual Anglonordic Life Science Conference
20-05-2021

Anglonordic is a great event to meet quality investors and companies - it is very well run and...